Plasma GFAP can be used as an accessible biomarker to monitor motor, non-motor, and cognitive performance and as an early potential biomarker to predict longitudinal motor and non-motor symptoms deterioration, cognitive decline, and postural instability in PD. This evidence concerns the gene GFAP and Postural instability.